Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments
Management call scheduled for Tuesday, August 13, 2024, at 8:30 AM ET
2024年8月13日週二上午8:30（美東時間）安排了管理者電話會議。
CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), today announced that it will host an investor call on Tuesday, August 13, 2024 at 8:30 am ET to discuss recent and upcoming developments.
2024年8月13日週二上午8:30（美東時間），思泰藥業公司（Citius Pharma）（或「公司」）（納斯達克代碼：CTXR）宣佈將主持單個投資者電話會議，以討論公司最新及即將發生的發展。
Citius Chairman and CEO, Leonard Mazur, will be joined by members of the management team. A question and answer period will follow management's discussion.
思泰公司董事長兼首席執行官Leonard Mazur將與管理團隊成員一同參加會議。管理團隊的討論結束後將設有問答環節。
Conference Call Details:
電話會議詳情：
|
Date: |
Tuesday, August 13, 2024 |
|
Time: |
8:30 a.m. Eastern Time |
|
Dial In: |
1-888-243-4451 (U.S. toll free) 1-412-542-4135 (international) |
|
Webcast: |
Register for the webcast here. A replay will be available on the Citius website () for 90 days following the event. |
|
日期： |
2024年8月13日星期二 |
|
時間： |
美國東部時間上午8:30 |
|
撥號： |
美國（免費）電話：1-888-243-4451 國際電話：1-412-542-4135 |
|
網絡直播： |
在此處註冊觀看網絡直播。本次活動結束後，可在思泰公司網站上回放90天。 |
About Citius Pharmaceuticals, Inc.
關於Citius Pharmaceuticals，Inc。
Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. For more information, please visit .
Citius Pharmaceuticals，Inc.是一家專注於開發和商業化首創重症監護產品的生物製藥公司。2024年8月，美國食品和藥品管理局批准LYMPHIR，一種用於治療表皮T細胞淋巴瘤的靶向免疫療法。Citius Pharma的後期管道還包括Mino-Lok，一種抗生素鎖定溶液，用於挽救導管相關性血流感染患者的導管，以及CITI-002（Halo-Lido），一種用於緩解痔瘡的局部製劑。 Mino-Lok的關鍵性3期試驗和Halo-Lido的20億期試驗在2023年完成。 Mino-Lok達到了其3期試驗的主要和次要終點。 Citius正在積極與FDA合作，以概述這兩個計劃的下一步。有關更多信息，請訪問網站。
Investor Contact:
投資者聯繫人：
Ilanit Allen
[email protected]
908-967-6677 x113
Ilanit Allen
[email protected]
908-967-6677 x113
Media Contact:
媒體聯繫人：
STiR-communications
Greg Salsburg
[email protected]
STiR-communications
Greg Salsburg
[email protected]
SOURCE Citius Pharmaceuticals, Inc.
來源：Citius Pharmaceuticals, Inc.
譯文內容由第三人軟體翻譯。